Adoptive cellular therapy after hematopoietic stem cell transplantation

Abstract

Effective cellular therapy using CD19 chimeric antigen receptor T‐cells for the treatment of advanced B‐cell malignancies raises the question of whether the administration of adoptive cellular therapy (ACT) posttransplant could reduce relapse and improve survival. Moreover, several early phase clinical studies have shown the potential beneficial effects of administration of tumor‐associated antigen‐specific T‐cells and natural killer cells posttransplant for high‐risk patients, aiming to decrease relapse and possibly improve survival. In this article, we present an in‐depth review of ACT after transplantation, which has the potential to significantly improve the efficacy of this procedure and revolutionize this field.